Structure Therapeutics

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Buoyed by new obesity data, Structure files $476m offering

Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million

News

NHS "isn't delivering equitable care for rare diseases"

A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks